Poster V. Levent Karabas


To evaluate the efficacy of intravitreal triamcinolone acetonite (IVT) injection versus intravitreal bevacizumab (IVB) injection in the management of subretinal fluid in patients with diabetic retinopathy.


Forty-seven patient affected by diabetic macular edema with subretinal fluid were included. Patients were assigned randomly to two groups. IVT group, patients who received 4mg/0.1ml intravitreal triamcinolone, and IVB group, patients who received 1.25mg/0.5ml bevacizumab. Macular thickness and subretinal fluid thickness were evaluated with Heidelberg Spectralis optical coherence tomography. Changes in the subretinal fluid thickness were the main outcome measure in this study.


Pre-injection macular thickness and subretinal fluid thickness was not statistically significantly different between the groups. Post-injection subretinal fluid thickness was statistically significantly lower in IVT group at 1-month follow up (mean 16.9 ±8.8 µm versus 68.83 ±22.76 µm). The subretinal thickness was not statistically significant different between the groups at 3-month follow up (21.08 ±9.3 µm versus 28.63 ±12.13 µm).


Intravitreal triamcinolone reduces subretinal fluid more effectively than intravitreal bevacizumab in diabetic patients at 1-month follow up. However there is no difference between groups at 3-month follow up.